13 Ways To Create A Sustainable Biosimilars Market In Europe
Executive Summary
More alignment between manufacturers and national payers is needed on issues such as price, competition and the role of payer guidance if the biosimilars market is to be sustainable over the longer term, says a new report.
You may also be interested in...
EU’s CHMP Expected To OK Another Biosimilar Humira
The European Medicines Agency’s CHMP is expected to give the green light to Samsung Bioepis’ biosimilar version of AbbVie’s anti-TNF-alpha Humira on June 23. Numerous other biosimilar developers have biosimilar adalimumabs under development in a bid to break into the $16bn market for the world’s top-selling drug.
EU’s CHMP Expected To OK Another Biosimilar Humira
The European Medicines Agency’s CHMP is expected to give the green light to Samsung Bioepis’ biosimilar version of AbbVie’s anti-TNF-alpha Humira on June 23. Numerous other biosimilar developers have biosimilar adalimumabs under development in a bid to break into the $16bn market for the world’s top-selling drug.
International Regulators Plan Roadmap For Collaborative RWE Studies
Experiences during the COVID-19 pandemic are expected to help identify future opportunities for regulatory cooperation on real-world evidence and avoid divergent decision-making for products including advanced therapies and personalized medicines.